Logo image of ALINS.PA

INTRASENSE SAS (ALINS.PA) Stock Fundamental Analysis

EPA:ALINS - Euronext Paris - Matif - FR0011179886 - Common Stock - Currency: EUR

0.2854  -0.01 (-2.86%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ALINS. ALINS was compared to 13 industry peers in the Health Care Technology industry. Both the profitability and financial health of ALINS have multiple concerns. ALINS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALINS has reported negative net income.
ALINS had a negative operating cash flow in the past year.
In the past 5 years ALINS always reported negative net income.
In the past 5 years ALINS always reported negative operating cash flow.
ALINS.PA Yearly Net Income VS EBIT VS OCF VS FCFALINS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -73.59%, ALINS is doing worse than 69.23% of the companies in the same industry.
Looking at the Return On Equity, with a value of -341.90%, ALINS is doing worse than 69.23% of the companies in the same industry.
Industry RankSector Rank
ROA -73.59%
ROE -341.9%
ROIC N/A
ROA(3y)-53.46%
ROA(5y)-37.03%
ROE(3y)-186.99%
ROE(5y)-123.56%
ROIC(3y)N/A
ROIC(5y)N/A
ALINS.PA Yearly ROA, ROE, ROICALINS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

With a Gross Margin value of 69.46%, ALINS perfoms like the industry average, outperforming 46.15% of the companies in the same industry.
ALINS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ALINS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.33%
GM growth 5Y-4.31%
ALINS.PA Yearly Profit, Operating, Gross MarginsALINS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

0

2. Health

2.1 Basic Checks

ALINS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALINS has been increased compared to 1 year ago.
ALINS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ALINS is higher compared to a year ago.
ALINS.PA Yearly Shares OutstandingALINS.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALINS.PA Yearly Total Debt VS Total AssetsALINS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

ALINS has an Altman-Z score of -1.21. This is a bad value and indicates that ALINS is not financially healthy and even has some risk of bankruptcy.
ALINS has a Altman-Z score of -1.21. This is in the lower half of the industry: ALINS underperforms 61.54% of its industry peers.
ALINS has a Debt/Equity ratio of 0.54. This is a neutral value indicating ALINS is somewhat dependend on debt financing.
ALINS has a Debt to Equity ratio (0.54) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Altman-Z -1.21
ROIC/WACCN/A
WACC7.68%
ALINS.PA Yearly LT Debt VS Equity VS FCFALINS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M

2.3 Liquidity

A Current Ratio of 0.48 indicates that ALINS may have some problems paying its short term obligations.
With a Current ratio value of 0.48, ALINS is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
A Quick Ratio of 0.48 indicates that ALINS may have some problems paying its short term obligations.
With a Quick ratio value of 0.48, ALINS is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.48
Quick Ratio 0.48
ALINS.PA Yearly Current Assets VS Current LiabilitesALINS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

4

3. Growth

3.1 Past

ALINS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.52%.
The Revenue for ALINS has decreased by -32.04% in the past year. This is quite bad
The Revenue has been decreasing by -7.51% on average over the past years.
EPS 1Y (TTM)-54.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-89.56%
Revenue 1Y (TTM)-32.04%
Revenue growth 3Y-18.74%
Revenue growth 5Y-7.51%
Sales Q2Q%-7.45%

3.2 Future

The Earnings Per Share is expected to grow by 27.48% on average over the next years. This is a very strong growth
ALINS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 49.68% yearly.
EPS Next Y37.5%
EPS Next 2Y27.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year71.49%
Revenue Next 2Y49.68%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALINS.PA Yearly Revenue VS EstimatesALINS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
ALINS.PA Yearly EPS VS EstimatesALINS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALINS. In the last year negative earnings were reported.
Also next year ALINS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALINS.PA Price Earnings VS Forward Price EarningsALINS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALINS.PA Per share dataALINS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1

4.3 Compensation for Growth

ALINS's earnings are expected to grow with 27.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALINS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTRASENSE SAS

EPA:ALINS (4/25/2025, 7:00:00 PM)

0.2854

-0.01 (-2.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)03-25 2025-03-25
Earnings (Next)07-24 2025-07-24
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.89%
Ins Owner ChangeN/A
Market Cap15.05M
Analysts40
Price Target0.24 (-15.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.7
P/FCF N/A
P/OCF N/A
P/B 9.1
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.04
BVpS0.03
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.59%
ROE -341.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.46%
FCFM N/A
ROA(3y)-53.46%
ROA(5y)-37.03%
ROE(3y)-186.99%
ROE(5y)-123.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.33%
GM growth 5Y-4.31%
F-Score1
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 169.4%
Cap/Sales 98.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.48
Quick Ratio 0.48
Altman-Z -1.21
F-Score1
WACC7.68%
ROIC/WACCN/A
Cap/Depr(3y)186.16%
Cap/Depr(5y)148.72%
Cap/Sales(3y)65.28%
Cap/Sales(5y)45.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-89.56%
EPS Next Y37.5%
EPS Next 2Y27.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.04%
Revenue growth 3Y-18.74%
Revenue growth 5Y-7.51%
Sales Q2Q%-7.45%
Revenue Next Year71.49%
Revenue Next 2Y49.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-59.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.37%
OCF growth 3YN/A
OCF growth 5YN/A